Current advances in Hodgkin's lymphoma
Tóm tắt
Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field.
Tài liệu tham khảo
10.1002/hon.723
10.1177/095952873201700106
10.1093/annonc/13.S1.79
10.1016/j.ijrobp.2013.05.005
10.1001/jama.1946.02870380008004
Carbone P.P., 1968, Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids, Cancer Res, 28, 811
10.7326/0003-4819-73-6-881
10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7
10.1056/NEJMoa022473
10.1056/NEJMoa1100340
10.1200/JCO.2015.64.5648
10.1182/blood.V128.22.1183.1183
10.1007/s12185-016-2080-5
Skoetz N., 2017, Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma, Cochrane Database Syst Rev, 5, CD007941
10.1200/JCO.1995.13.5.1080
10.1200/JCO.2012.43.4803
10.1182/blood-2017-10-811224
10.1007/s40265-017-0705-5
10.1200/JCO.2017.76.0793
10.1056/NEJMoa1510093
10.1016/S0140-6736(17)32134-7
10.1056/NEJMoa1408648
10.1056/NEJMoa1708984
10.1182/blood-2016-03-703470
10.1182/blood.V130.Suppl_1.734.734
10.1016/S1470-2045(17)30696-4
10.1016/S0140-6736(11)61940-5
10.1002/hon.2437_69
10.1200/jco.2015.33.15_suppl.8505
10.1002/hon.2437_68
10.1182/blood-2015-06-644336
10.1182/blood-2017-06-787200
10.1200/JCO.2011.38.0410
10.1182/blood-2016-02-699850
10.1016/S0140-6736(15)60165-9
10.1016/j.bbmt.2015.11.315
10.1182/blood.V130.Suppl_1.738.738
10.1182/blood-2017-11-815183
10.1182/blood.V128.22.4146.4146
10.1182/blood.V128.22.1109.1109
10.1182/blood.V128.22.1834.1834
10.1200/JCO.2016.72.1316
10.1200/JCO.2018.36.15_suppl.7537
Ansell S.M., 2017, A phase 1 study investigating the combination of AFM13 and the monoclonal anti‐PD‐1 antibody pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure: data from the dose escalation part of the study, Blood, 13, 1522
10.1200/JCO.2018.36.15_suppl.7536
10.1186/s13045-015-0188-3
10.1182/blood-2014-12-614636
10.1002/path.1725
10.1186/s40164-018-0103-z
10.1182/blood-2010-05-282780
10.1182/blood.V128.22.1820.1820
10.3324/haematol.2017.180554
10.1056/NEJMc1505857
10.1182/blood-2013-06-507947
10.1186/1756-8722-2-36
10.1182/blood-2011-07-362475
10.1200/JCO.2013.51.5304
10.1172/JCI94306
10.1158/1078-0432.CCR-16-1365